Statistics of Non-small Cell Lung Cancer

The most frequent kind of lung cancer is non-small cell lung cancer (NSCLC). It accounts for 84 percent of all lung cancer diagnoses. Small cell lung cancer and non-small cell lung cancer are included in the statistics for lung cancer provided below. Lung cancer can be diagnosed in an estimated 2.3 million people worldwide this year. In the United States, an estimated 235,760 adults (119,100 males and 116,660 women) will be diagnosed.

In the United States, tens of thousands of people are cured of NSCLC each year. Furthermore, some advanced lung cancer patients can live for many years after being diagnosed. Patients who are told their lung cancer is incurable can live longer than those who are told their lung cancer is treatable. The essential thing to remember is that lung cancer may be treated at any stage. And these treatments have been shown to extend people’s lives and improve their quality of life.

Lung cancer accounts for around a quarter of all cancer fatalities. However, since 1990, men’s mortality rates have decreased by 54%, while women’s mortality rates have decreased by 30% since 2002. Each year from 2014 to 2018, the death rate for males with lung cancer decreased by 5%. Lung cancer death rates for women have been declining at a pace of 4% each year. More people are not smoking, more people are quitting smoking, and medical breakthroughs in diagnosis and treatment, according to research.

5-year Survival Rate

The 5-year survival rate indicates the percentage of persons who live for at least five years after the cancer diagnosis. The percentage refers to how many out of 100 something is. The 5-year survival rate for all persons with lung cancer, regardless of form, is 21%.

It’s crucial to remember, however, that survival rates vary depending on various circumstances, including the type of lung cancer and the stage of the disease. The overall 5-year survival percentage for those with localized NSCLC, which indicates the disease has not moved outside of the lung, is 63 percent. The 5-year survival rate for regional NSCLC, which indicates cancer has migrated outside of the lung to adjacent lymph nodes, is around 35%. The 5-year survival rate for cancer spread to other parts of the body, known as metastatic lung cancer, is 7 percent. Newer therapies, such as targeted treatments and immunotherapies, are allowing people with metastatic lung cancer to live longer than ever before.

It’s vital to remember that numbers on NSCLC survival rates are only estimates. The figure is based on annual data on the number of people in the United States who have this cancer. Experts also assess survival data every five years. As a result, the estimate may not reflect the outcomes of improved diagnosis or therapy that has been available for less than five years.